Skip to main content
main-content
Top

Tip

Swipe om te navigeren naar een ander artikel

Gepubliceerd in: Quality of Life Research 9/2021

17-05-2021

The impact of idiopathic pulmonary fibrosis on health state utility values: evidence from Australia

Auteurs: Ingrid A. Cox, Barbara de Graaff, Hasnat Ahmed, Julie Campbell, Petr Otahal, Tamera J. Corte, Ian Glaspole, Yuben Moodley, Nicole Goh, Sacha Macansh, E. Haydn Walters, Andrew J. Palmer

Gepubliceerd in: Quality of Life Research | Uitgave 9/2021

Log in om toegang te krijgen
share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail

Abstract

Purpose

Idiopathic pulmonary fibrosis (IPF) is a progressive and universally fatal lung disease, characterised by increasing fibrosis of the lung parenchyma. In this study, we aimed to quantify the health state utility values (HSUVs) for Australians with IPF and to identify the factors affecting these HSUVs.

Methods

Participants of the Australian IPF Registry (AIPFR), with data on EuroQoL five dimension—five level (EQ-5D-5L) profiles were included. Pulmonary function tests (PFTs) were used to assess disease severity using three IPF -based classification systems. Stepwise multivariable linear regression models assessed the relationship between HSUVs and important demographic and clinical parameters.Query

Results

A total of 155 participants provided data for the analysis of HSUVs. For our base case, HSUVs ranged from − 0.57 to 1.00. Mean HSUVs for all participants was 0.65 (95% CI 0.61–0.70). In general, HSUVs decreased with increasing disease severity under all disease severity classification systems. Multivariable linear regression demonstrated a negative association between HSUVs, disease severity and having more than 2 comorbidities.

Conclusions

Our study has shown that EQ-5D-5L has exhibited discriminatory sensitivity for the study population. We have demonstrated that disease severity and having more than two comorbidities was associated with lower HSUVs in Australians with IPF. Our findings support early diagnosis and appropriate evidence-based treatment to slow or prevent IPF progression; and identification and treatment of associated comorbidities to potentially improve health-related quality of life in people with IPF.
Bijlagen
Alleen toegankelijk voor geautoriseerde gebruikers
Literatuur
8.
go back to reference Jo, H. E., Glaspole, I., Grainge, C., Goh, N., Hopkins, P. M., Moodley, Y., Reynolds, P. N., Chapman, S., Walters, E. H., Zappala, C., & Allan, H. (2017). Baseline characteristics of idiopathic pulmonary fibrosis: Analysis from the Australian Idiopathic Pulmonary Fibrosis Registry. European Respiratory Journal, 49(2), 02. https://​doi.​org/​10.​1183/​13993003.​01592-2016. CrossRef Jo, H. E., Glaspole, I., Grainge, C., Goh, N., Hopkins, P. M., Moodley, Y., Reynolds, P. N., Chapman, S., Walters, E. H., Zappala, C., & Allan, H. (2017). Baseline characteristics of idiopathic pulmonary fibrosis: Analysis from the Australian Idiopathic Pulmonary Fibrosis Registry. European Respiratory Journal, 49(2), 02. https://​doi.​org/​10.​1183/​13993003.​01592-2016. CrossRef
14.
go back to reference Wells, A. U., Desai, S. R., Rubens, M. B., Goh, N. S., Cramer, D., Nicholson, A. G., Colby, T. V., Du Bois, R. M., & Hansell, D. M. (2013). Idiopathic pulmonary fibrosis: A composite physiologic index derived from disease extent observed by computed tomography. American Journal of Respiratory and Critical Care Medicine, 167(7), 962–969. https://​doi.​org/​10.​1164/​rccm.​2111053. CrossRef Wells, A. U., Desai, S. R., Rubens, M. B., Goh, N. S., Cramer, D., Nicholson, A. G., Colby, T. V., Du Bois, R. M., & Hansell, D. M. (2013). Idiopathic pulmonary fibrosis: A composite physiologic index derived from disease extent observed by computed tomography. American Journal of Respiratory and Critical Care Medicine, 167(7), 962–969. https://​doi.​org/​10.​1164/​rccm.​2111053. CrossRef
18.
go back to reference R Core Team. (2019). R: A language and environment for statistical computing. (3.5.1). Vienna: R Foundation for Statistical Computing. R Core Team. (2019). R: A language and environment for statistical computing. (3.5.1). Vienna: R Foundation for Statistical Computing.
20.
go back to reference StataCorp. (2019). Stata statistical software: Release 16. Texas: StataCorp LLC. StataCorp. (2019). Stata statistical software: Release 16. Texas: StataCorp LLC.
26.
go back to reference Jo, H. E., Troy, L. K., Keir, G., Chambers, D. C., Holland, A., Goh, N., Wilsher, M., De Boer, S., Moodley, Y., Grainge, C., & Whitford, H. (2017). Treatment of idiopathic pulmonary fibrosis in Australia and New Zealand: A position statement from the Thoracic Society of Australia and New Zealand and the Lung Foundation Australia. Respirology, 22(7), 1436–1458. https://​doi.​org/​10.​1111/​resp.​13146. CrossRefPubMed Jo, H. E., Troy, L. K., Keir, G., Chambers, D. C., Holland, A., Goh, N., Wilsher, M., De Boer, S., Moodley, Y., Grainge, C., & Whitford, H. (2017). Treatment of idiopathic pulmonary fibrosis in Australia and New Zealand: A position statement from the Thoracic Society of Australia and New Zealand and the Lung Foundation Australia. Respirology, 22(7), 1436–1458. https://​doi.​org/​10.​1111/​resp.​13146. CrossRefPubMed
27.
go back to reference Raghu, G., Rochwerg, B., Zhang, Y., Garcia, C. A., Azuma, A., Behr, J., Brozek, J. L., Collard, H. R., Cunningham, W., Homma, S., & Johkoh, T. (2015). An official ATS/ERS/JRS/ALAT clinical practice guideline: Treatment of idiopathic pulmonary fibrosis. An update of the 2011 clinical practice guideline. American Journal of Respiratory and Critical Care Medicine, 192(2), e3–e19. https://​doi.​org/​10.​1164/​rccm.​201506-1063ST. CrossRefPubMed Raghu, G., Rochwerg, B., Zhang, Y., Garcia, C. A., Azuma, A., Behr, J., Brozek, J. L., Collard, H. R., Cunningham, W., Homma, S., & Johkoh, T. (2015). An official ATS/ERS/JRS/ALAT clinical practice guideline: Treatment of idiopathic pulmonary fibrosis. An update of the 2011 clinical practice guideline. American Journal of Respiratory and Critical Care Medicine, 192(2), e3–e19. https://​doi.​org/​10.​1164/​rccm.​201506-1063ST. CrossRefPubMed
28.
go back to reference Raghu, G., Remy-Jardin, M., Myers, J. L., Richeldi, L., Ryerson, C. J., Lederer, D. J., Behr, J., Cottin, V., Danoff, S. K., Morell, F., & Flaherty, K. R. (2018). Diagnosis of idiopathic pulmonary fibrosis. An official ATS/ERS/JRS/ALAT clinical practice guideline. American Journal of Respiratory and Critical Care Medicine, 198(5), e44–e68. https://​doi.​org/​10.​1164/​rccm.​201807-1255ST. CrossRefPubMed Raghu, G., Remy-Jardin, M., Myers, J. L., Richeldi, L., Ryerson, C. J., Lederer, D. J., Behr, J., Cottin, V., Danoff, S. K., Morell, F., & Flaherty, K. R. (2018). Diagnosis of idiopathic pulmonary fibrosis. An official ATS/ERS/JRS/ALAT clinical practice guideline. American Journal of Respiratory and Critical Care Medicine, 198(5), e44–e68. https://​doi.​org/​10.​1164/​rccm.​201807-1255ST. CrossRefPubMed
32.
go back to reference Glaspole, I. N., Chapman, S. A., Cooper, W. A., Ellis, S. J., Goh, N. S., Hopkins, P. M., Macansh, S., Mahar, A., Moodley, Y. P., Paul, E., Reynolds, P. N., Walters, E. H., Zappala, C. J., & Corte, T. J. (2017). Health-related quality of life in idiopathic pulmonary fibrosis: Data from the Australian IPF Registry. Respirology, 22(5), 950–956. https://​doi.​org/​10.​1111/​resp.​12989. CrossRefPubMed Glaspole, I. N., Chapman, S. A., Cooper, W. A., Ellis, S. J., Goh, N. S., Hopkins, P. M., Macansh, S., Mahar, A., Moodley, Y. P., Paul, E., Reynolds, P. N., Walters, E. H., Zappala, C. J., & Corte, T. J. (2017). Health-related quality of life in idiopathic pulmonary fibrosis: Data from the Australian IPF Registry. Respirology, 22(5), 950–956. https://​doi.​org/​10.​1111/​resp.​12989. CrossRefPubMed
34.
go back to reference King, T. E., Jr., Behr, J., Brown, K. K., du Bois, R. M., Lancaster, L., de Andrade, J. A., Stahler, G., Leconte, I., Roux, S., & Raghu, G. (2008). BUILD-1: A randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis. American Journal of Respiratory & Critical Care Medicine, 177(1), 75–81. CrossRef King, T. E., Jr., Behr, J., Brown, K. K., du Bois, R. M., Lancaster, L., de Andrade, J. A., Stahler, G., Leconte, I., Roux, S., & Raghu, G. (2008). BUILD-1: A randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis. American Journal of Respiratory & Critical Care Medicine, 177(1), 75–81. CrossRef
35.
go back to reference King, T. E., Jr., Brown, K. K., Raghu, G., du Bois, R. M., Lynch, D. A., Martinez, F., Valeyre, D., Leconte, I., Morganti, A., Roux, S., & Behr, J. (2011). BUILD-3: A randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis. American Journal of Respiratory & Critical Care Medicine, 184(1), 92–99. https://​doi.​org/​10.​1164/​rccm.​201011-1874OC. CrossRef King, T. E., Jr., Brown, K. K., Raghu, G., du Bois, R. M., Lynch, D. A., Martinez, F., Valeyre, D., Leconte, I., Morganti, A., Roux, S., & Behr, J. (2011). BUILD-3: A randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis. American Journal of Respiratory & Critical Care Medicine, 184(1), 92–99. https://​doi.​org/​10.​1164/​rccm.​201011-1874OC. CrossRef
39.
go back to reference Kreuter, M., Swigris, J., Pittrow, D., Geier, S., Klotsche, J., Prasse, A., Wirtz, H., Koschel, D., Andreas, S., Claussen, M., Grohé, C., Wilkens, H., Hagmeyer, L., Skowasch, D., Meyer, J. F., Kirschner, J., Gläser, S., Herth, F. J. F., Welte, T.,…Behr, J. (2017). Health related quality of life in patients with idiopathic pulmonary fibrosis in clinical practice: Insights-IPF registry. Respiratory Research, 18(1), 139. https://​doi.​org/​10.​1186/​s12931-017-0621-y. CrossRefPubMedPubMedCentral Kreuter, M., Swigris, J., Pittrow, D., Geier, S., Klotsche, J., Prasse, A., Wirtz, H., Koschel, D., Andreas, S., Claussen, M., Grohé, C., Wilkens, H., Hagmeyer, L., Skowasch, D., Meyer, J. F., Kirschner, J., Gläser, S., Herth, F. J. F., Welte, T.,…Behr, J. (2017). Health related quality of life in patients with idiopathic pulmonary fibrosis in clinical practice: Insights-IPF registry. Respiratory Research, 18(1), 139. https://​doi.​org/​10.​1186/​s12931-017-0621-y. CrossRefPubMedPubMedCentral
42.
43.
go back to reference Idiopathic Pulmonary Fibrosis Clinical Research Network, Zisman, D. A., Schwarz, M., Anstrom, K. J., Collard, H. R., Flaherty, K. R., & Hunninghake, G. W. (2010). A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis. New England Journal of Medicine, 363(7), 620–628. https://​doi.​org/​10.​1056/​NEJMoa1002110. CrossRef Idiopathic Pulmonary Fibrosis Clinical Research Network, Zisman, D. A., Schwarz, M., Anstrom, K. J., Collard, H. R., Flaherty, K. R., & Hunninghake, G. W. (2010). A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis. New England Journal of Medicine, 363(7), 620–628. https://​doi.​org/​10.​1056/​NEJMoa1002110. CrossRef
48.
go back to reference Wapenaar, M., Patel, A. S., Birring, S. S., et al. (2017). Translation and validation of the King's Brief Interstitial Lung Disease (K-BILD) questionnaire in French, Italian, Swedish, and Dutch. Chronic Respiratory Disease, 14(2), 140–150. CrossRef Wapenaar, M., Patel, A. S., Birring, S. S., et al. (2017). Translation and validation of the King's Brief Interstitial Lung Disease (K-BILD) questionnaire in French, Italian, Swedish, and Dutch. Chronic Respiratory Disease, 14(2), 140–150. CrossRef
Metagegevens
Titel
The impact of idiopathic pulmonary fibrosis on health state utility values: evidence from Australia
Auteurs
Ingrid A. Cox
Barbara de Graaff
Hasnat Ahmed
Julie Campbell
Petr Otahal
Tamera J. Corte
Ian Glaspole
Yuben Moodley
Nicole Goh
Sacha Macansh
E. Haydn Walters
Andrew J. Palmer
Publicatiedatum
17-05-2021
Uitgeverij
Springer International Publishing
Gepubliceerd in
Quality of Life Research / Uitgave 9/2021
Print ISSN: 0962-9343
Elektronisch ISSN: 1573-2649
DOI
https://doi.org/10.1007/s11136-021-02879-1